For the second time in less than a week, the Cambridge, Mass., biotech startup Dicerna Pharmaceuticals has cut a licensing deal with a big drug maker — this time, it’s Eli Lilly (LLY).
Lilly, the global pharmaceutical giant based in Indianapolis, planned to announce Monday a collaboration with Dicerna to discover, develop, and market new medicines to treat heart disease, diabetes, chronic liver diseases, and neurodegenerative disorders.
